Search

everythinglearnresearchcommunity

for

Search:↓

An 18-year-old male with hair loss is considering starting finasteride but is concerned about potential side effects like gynecomastia due to his prolactin levels. He seeks guidance on whether his bloodwork indicates it's safe to begin treatment.

The user is trying topical melatonin for hair loss and reports feeling tired and unmotivated, considering using it only at night due to restlessness. No hair regrowth noticed after 4 days.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The conversation is about the proper frequency and needle length for microneedling to treat hair loss, with a user asking if they should use a 0.5 mm derma stamp daily and a 1.5 mm stamp once a week.

The user experienced significant hair growth using 0.5 mg Dutasteride and 5 mg oral Minoxidil over 10 weeks, with initial shedding but no side effects. The treatment was surprisingly affordable at $7 for a 3-month supply.

The user has been using finasteride for 5 months without hair regrowth or loss and is considering adding dermarolling to their regimen. They are seeking advice on the effectiveness of finasteride with dermarolling, the type of dermaroller to use, aftercare products, and concerns about shedding from dermarolling alone.

The user successfully overcame finasteride side effects by lowering the dosage and adding zinc and vitamin B6 supplements. They also micro-dosed dutasteride and resumed weight lifting.

A user experienced excessive hair shedding after taking 17 mg of Zinc gluconate daily for acne. They are seeking advice on similar experiences and solutions.

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.